Amgen, Colorectal Cancer and US FDA
FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation
The Food and Drug Administration approved Amgen Inc ‘s AMGN Lumakras (sotorasib) in combination with Vectibix (panitumumab) for KRAS G12C-mutated metastatic colorectal cancer (mCRC), who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan- based chemotherapy .
We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...
Piper Sandler reiterated its Overweight rating on Amgen (NASDAQ:AMGN) shares, maintaining a price target of $310.00. The company, which boasts a "GOOD" overall financial health score according to ...
Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $268.94 which represents a slight increase of $1.84 or 0.69% from the prior close of $267.1. The stock opened at $269.33 and touched a low ...
Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...
Amgen Inc. closed $79.75 short of its 52-week high ($346.85), which the company achieved on July 25th.
The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After ...
Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical ...
Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback